glp-1 stomach paralysis law firm in kentucky Mounjaro and Ozempic Lawyer What You Need to Know

Participants on semaglutide lost an average of approximately 14.9% of body weight at 68 weeks compared with placebo

GLP-1 drugs reduce appetite, meaning consumers eat less

Confirmation through blood tests Laboratory evidence supports these population-level trends

In hEDS-associated neuropathic POTS where partial sympathetic denervation of the lower extremity vasculature produces blunted vasoconstriction, blood already pools in peripheral capacitance vessels on standing, stroke volume is structurally reduced, and the sympathetic nervous system is already operating near its compensation ceiling the additional vasodilatory and chronotropic load imposed by chronic dual incretin receptor agonism may have limited physiological reserve to absorb it